Injectable treatments for high cholesterol
Pro Research Analysisby 
Searched over 200M research papers
Injectable Treatments for High Cholesterol: Key Options and Efficacy
PCSK9 Inhibitors: Evolocumab, Alirocumab, and Ongaricimab
Injectable PCSK9 inhibitors, such as evolocumab, alirocumab, and the newer ongericimab, are widely used for patients who do not reach cholesterol goals with statins or are statin-intolerant. These drugs are monoclonal antibodies that target the PCSK9 protein, leading to significant reductions in low-density lipoprotein cholesterol (LDL-C). Clinical studies show that these agents can lower LDL-C by 50% or more, with ongericimab demonstrating reductions of over 70% in some patient groups. These treatments are generally well tolerated, with mild injection site reactions being the most common side effect. Serious adverse events are rare and occur at similar rates as placebo groups Strilchuk2019Zhao2024Zeng2024.
Inclisiran: Small Interfering RNA (siRNA) Injectable
Inclisiran is a novel injectable therapy that uses small interfering RNA to inhibit the production of PCSK9 in the liver. It is administered twice a year and is approved for adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia who require further LDL-C reduction despite maximally tolerated statin therapy. Clinical trials have shown that inclisiran can reduce LDL-C by 40–50% and has a favorable safety profile, with the most common side effects being mild injection site reactions. Its twice-yearly dosing is expected to improve patient adherence compared to more frequent injections required by monoclonal antibodies Hughes-Hubley2022Larkin20226+1 MORE.
Other Injectable Agents: Antisense Oligonucleotides and ANGPTL3 Inhibitors
Other injectable options include antisense oligonucleotides (such as mipomersen and volanesorsen) and drugs targeting angiopoietin-like protein 3 (ANGPTL3), like evinacumab. These agents are primarily used in patients with severe inherited forms of hypercholesterolemia. While they show promise in lowering cholesterol, their safety profiles are less well established, especially in patients with multiple health conditions or those taking many medications .
Alternative and Experimental Injectable Therapies
Research into alternative injectable treatments includes agents like intravenous curcumin and Danhong injection, which have shown cholesterol-lowering effects in animal studies. Injectable curcumin significantly reduced LDL-C and improved atherosclerotic lesions in rabbits, while Danhong injection improved lipid profiles and liver health in rats. However, these treatments are not yet established for routine clinical use in humans Momtazi-Borojeni2019Du2021.
Usage Trends and Economic Considerations
The use of injectable cholesterol-lowering drugs is increasing, especially as more patients require additional LDL-C reduction beyond what statins can provide. However, the high cost of these injectables means that oral alternatives like bempedoic acid are sometimes used first to delay the need for more expensive injectable therapies .
Conclusion
Injectable treatments for high cholesterol, including PCSK9 inhibitors (evolocumab, alirocumab, ongericimab) and inclisiran, offer effective options for patients who cannot achieve cholesterol goals with statins alone. These therapies provide substantial LDL-C reductions and are generally safe, with mild injection site reactions being the most common side effect. Newer and experimental injectables are under investigation, but their use is currently limited. The choice of therapy often depends on individual patient needs, cost, and the degree of LDL-C lowering required Hughes-Hubley2022Strilchuk2019Larkin2022+5 MORE.
Sources and full results
Most relevant research papers on this topic